Co-Diagnostics, Inc Chief Scientific Officer to Address Bipartisan Commission on Biodefense in Washington, D.C.
March 12 2020 - 6:30AM
Business Wire
Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular
diagnostics company with a unique, patented platform for the
development of diagnostic tests, announced today that Dr. Brent
Satterfield PhD, Chief Scientific Officer and co-founder of
Co-Diagnostics, will address a meeting held by the Bipartisan
Commission on Biodefense in Washington, D.C. on March 18, 2020. The
focus of the meeting will be to address national biodefense in
light of the response to COVID-19, and its implications for
preparedness.
Co-Diagnostics was the first U.S. company to receive a CE-mark
for a COVID-19 diagnostic test. The Company is currently shipping
orders for its test to countries on 5 continents, including
shipments to Italy, the most severely impacted country in the
European Union. The Company continues to scale up production to
meet global demand, and is also seeking emergency use clearance for
use as an in vitro diagnostic by the U.S. FDA as well as by the
CDSCO in India, both of which are expected to further increase the
domestic and international reach of this powerful and
cost-effective diagnostic tool.
The rapid development of the Company’s COVID-19 test was made
possible by a unique, proprietary design process and patented
CoPrimer™ technology platform that was invented by Dr. Satterfield.
Prior to founding Co-Diagnostics in 2013, Dr. Satterfield developed
new diagnostic platforms for groups such as the Department of
Homeland Security, the National Biodefense Analysis and
Countermeasures Center, the United States Army Medical Research
Institute of Infectious Disease, Sandia National Laboratories, the
California Department of Public Health and numerous others.
Dr. Satterfield remarked, “I am pleased to present the details
of the rapid development of our COVID-19 test to the Bipartisan
Commission on Biodefense. The Company’s proprietary platform serves
as a template to develop other tests needed now, and in the future
as new pathogens surface in our interconnected world. Our current
test detects COVID-19 with a high level of specificity to
distinguish it from similar viruses. However, in addition to
recently being declared a pandemic by the World Health
Organization, the virus that causes COVID-19 is also believed to be
mutating. Co-Diagnostics’ patented CoPrimer technology is uniquely
suited to quickly develop multiplex assays that can identify
multiple mutations of the virus in a single test when the need
arises. Rapid, efficient development of multiplexed tests is a core
competency of Co-Diagnostics.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding the (i) use of
funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in certain verticals or markets, (iv)
capital resources and runway needed to advance the Company’s
products and markets, (v) increased sales in the near-term, (vi)
flexibility in managing the Company’s balance sheet, (vii)
anticipation of business expansion, and (viii) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200312005274/en/
Company Contact: Andrew Benson Head of Investor Relations
+1 801-438-1036 investors@codiagnostics.com
Media Contact: Jennifer Webb Coltrin & Associates,
Inc +1 267-912-1173 jennifer_webb@coltrin.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024